You searched for: benchmrk (Danska - Engelska)

benchmrk 1 og 2 - poolet 48 uger 96 uger
benchmrk 1 and 2 pooled 48 weeks 96 weeks

Årsager til variabiliteten i benchmrk studiet kan omfatte forskelle i samtidig administration af mad og medicin.
sources of variability within the benchmrk study may include differences in co-administration with food and concomitant medicines.

virkning af isentress hos behandlingserfarne patienter benchmrk 1 og benchmrk 2 (igangværende, randomiserede, multicenter, dobbeltblindede, placebokontrollerede undersøgelser) vurderer sikkerheden og den antiretrovirale aktivitet af isentress 400 mg to gange dagligt versus placebo i en kombination med obt hos hiv- inficerede patienter, i alderen 16 år og ældre, der har dokumenteret resistens over for mindst ét lægemiddel i hver af de 3 klasser (nrtiere, nnrtiere, piere) af antiretroviral terapi.
clinical experience efficacy of isentress in treatment-experienced patients benchmrk 1 and benchmrk 2 (ongoing multi-centre, randomised, double-blind, placebo- controlled trials) evaluate the safety and anti-retroviral activity of isentress 400 mg b. i. d. vs. placebo in a combination with optimized background therapy (obt), in hiv-infected patients, 16 years or older, with documented resistance to at least 1 drug in each of 3 classes (nrtis, nnrtis, pis) of anti-retroviral therapies.